TY - JOUR
T1 - JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines
T2 - Process and product
AU - Braun, Lynne T.
AU - Saseen, Joseph J.
AU - Orringer, Carl E.
AU - Stone, Neil J.
AU - Guyton, John R.
N1 - Funding Information:
Dr. Braun, Dr. Saseen, Dr. Orringer, and Dr. Stone report no relevant disclosures or funding sources; Dr. Guyton has received research support from Sanofi, Regeneron, and Amarin.
Publisher Copyright:
© 2019
PY - 2019/5/1
Y1 - 2019/5/1
N2 - In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.
AB - In this NLA Roundtable four members of the writing committee join the Editor to discuss the process of developing the AHA/ACC/Multisociety Cholesterol Guidelines, which were unveiled in November 2018. They also provide personal insights on the finished product. Highlights include 1) the committee's decision to summarize 10 take-home messages providing rapid communication of key points, 2) emphasis on clinician -patient discussion, which may bring up issues specific to women or other population groups at risk, 3) personalizing risk with risk-enhancing factors such as LDL-C ≥ 160 mg/dl, metabolic syndrome, chronic kidney disease, pre-eclampsia, premature menopause, high risk ethnicity, inflammatory diseases, hypertriglyceridemia and in selected cases, Lp(a), hs-CRP and apoB; 4) using coronary artery calcium scoring when a risk decision is uncertain in intermediate risk patients 5) monitoring for goals of moderate or intensive LDL cholesterol reduction, 6) thresholds for adding nonstatin LDL-lowering therapy in those at very high risk or for heterozygous familial hypercholesterolemia and 7) cost value assessment for expensive treatment.
KW - Cholesterol guidelines
KW - Coronary calcium scoring
KW - Cost value assessment
KW - Evidence-based medicine
KW - Lipid clinical practice
KW - Risk-enhancing factors
UR - http://www.scopus.com/inward/record.url?scp=85067449315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067449315&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2019.05.008
DO - 10.1016/j.jacl.2019.05.008
M3 - Review article
C2 - 31229021
AN - SCOPUS:85067449315
VL - 13
SP - 345
EP - 355
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
SN - 1933-2874
IS - 3
ER -